| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on August 2, 2005
Accepted on October 7, 2005
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, and; Human Cancer Genetics Program, The Ohio State University, Columbus, OH 43210
* To whom correspondence should be addressed. E-mail: Lawrence.Kirschner{at}osumc.edu.
Context: Adrenocortical carcinoma (ACC) is a rare cancer, but one that has devastating consequences for affected patients. Surgery is the mainstay of therapy, although the high frequency of metastatic disease implies that it is frequently non-curative. Traditional cytotoxic chemotherapy for ACC has generally produced disappointing responses, implying the need for the new therapies for this disease.
Evidence Acquisition: Review articles and primary literature were identified by extensive PubMed searching to obtain papers evaluating the current state of knowledge regarding ACC, as well as assessing the development of new therapeutic modalities for the treatment of cancer. When needed, further articles were identified from the reference lists of the papers obtained from the primary screen.
Evidence Synthesis: Multiple new modalities that may enhance the future treatment of ACC were identified. They include: combating drug resistance, targeting tumor vasculature, inhibiting signaling pathways with small molecules, and using gene and/or immunotherapy. This review provides a brief summary of the progress and prospects of each of these modalities, and focuses on emerging data and treatments that may alter the course of this disease within the next few years.
Conclusions: Despite the current grim outlook, the recent applications of emerging technology to the study of ACC and the development of newer, "targeted" therapies for cancer suggests the possibility of a new hope for patients with this disease, although these therapies will need to be evaluated by rigorous clinical trials to verify their effectiveness.
This article has been cited by other articles:
 |
|
 |
|
  M. Q. Almeida, M. C. B. V. Fragoso, C. F. P. Lotfi, M. G. Santos, M. Y. Nishi, M. H. S. Costa, A. M. Lerario, C. C. Maciel, G. E. Mattos, A. A. L. Jorge, et al. Expression of Insulin-Like Growth Factor-II and Its Receptor in Pediatric and Adult Adrenocortical Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3524 - 3531. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Volante, C Buttigliero, E Greco, A Berruti, and M Papotti Pathological and molecular features of adrenocortical carcinoma: an update J. Clin. Pathol., July 1, 2008; 61(7): 787 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Else, T. J. Giordano, and G. D. Hammer Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1442 - 1449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Doghman, T. Karpova, G. A. Rodrigues, M. Arhatte, J. De Moura, L. R. Cavalli, V. Virolle, P. Barbry, G. P. Zambetti, B. C. Figueiredo, et al. Increased Steroidogenic Factor-1 Dosage Triggers Adrenocortical Cell Proliferation and Cancer Mol. Endocrinol., December 1, 2007; 21(12): 2968 - 2987. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. D. Delhanty, P. M. van Koetsveld, C. Gauna, B. van de Zande, G. Vitale, L. J. Hofland, and A. J. van der Lely Ghrelin and its unacylated isoform stimulate the growth of adrenocortical tumor cells via an anti-apoptotic pathway Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E302 - E309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Libe, A. Fratticci, and J. Bertherat Adrenocortical cancer: pathophysiology and clinical management Endocr. Relat. Cancer, March 1, 2007; 14(1): 13 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ohwada, M. Izumi, S. Kawate, K. Hamada, H. Toya, N. Togo, J. Horiguchi, Y. Koibuchi, T. Takahashi, and M. Yamada Surgical Outcome of Stage III and IV Adrenocortical Carcinoma Jpn. J. Clin. Oncol., February 2, 2007; (2007) hyl127v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Kirschner Paradigms for adrenal cancer: think globally, act locally. J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4250 - 4252. [Full Text] [PDF]
|
|
|
|
|
|
P. M. van Koetsveld, G. Vitale, W. W. de Herder, R. A. Feelders, K. van der Wansem, M. Waaijers, C. H. J. van Eijck, E.-J. M. Speel, E. Croze, A.-J. van der Lely, et al. Potent Inhibitory Effects of Type I Interferons on Human Adrenocortical Carcinoma Cell Growth J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4537 - 4543. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
